跳至主要内容
临床试验/2026-526109-13-00
2026-526109-13-00撤回3 期

Impact of Hyperthermic Intrathoracic Chemotherapy (HITHOC) and Pleurectomy in the local treatment of pleural tumors. A Prospective Randomized Study The Tic-Tac Trial

Universita' Degli Studi Di Torino1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2026年7月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
撤回
入组人数
64
试验地点
1
主要终点
The primary endpoint is progression-free survival. The comparison will be performed between the treatment group (HITHOC, n = 32) and the control group (chemical pleurodesis or indwelling pleural catheter placement, n = 32).

研究概览

简要总结

The primary objective is to compare hyperthermic intrathoracic chemotherapy, with or without pleurectomy, versus standard treatment (chemical pleurodesis or indwelling pleural catheter placement) in terms of progression-free survival (PFS) in a population of 64 patients affected by malignant pleural effusion.

研究设计

分配方式
Randomized
主要目的
Enrolment of Eligible Patients
盲法
None

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Patients aged >18 years
  • Scheduled diagnostic thoracoscopy for malignant pleural effusion
  • Good general clinical conditions (LENT score 1–2)

排除标准

  • Presence of active pulmonary or systemic infection
  • ● Presence of any condition that, in the investigator’s judgment, may jeopardize the subject’s well-being and/or negatively affect the interpretation of data collected during the clinical study;
  • Inability to comply with study requirements or the follow-up schedule

结局指标

主要结局

The primary endpoint is progression-free survival. The comparison will be performed between the treatment group (HITHOC, n = 32) and the control group (chemical pleurodesis or indwelling pleural catheter placement, n = 32).

The primary endpoint is progression-free survival. The comparison will be performed between the treatment group (HITHOC, n = 32) and the control group (chemical pleurodesis or indwelling pleural catheter placement, n = 32).

次要结局

  • Comparison of quality of life
  • Comparison of overall survival
  • Comparison of progression-free survival in patients with isolated parietal pleural disease undergoing HITHOC plus pleurectomy versus HITHOC alone through a second randomization
  • Assessment of the accuracy and prognostic correlation of the intraoperative pleural disease dissemination score. This endpoint will be measured in all the patientsi

研究者

申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

Francesco Leo

Scientific

Universita' Degli Studi Di Torino

研究点 (1)

Loading locations...

相似试验